Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol for secondary hyperparathyroidism in hemodialysis patients (multicenter registry)
ChiCTR2000034476Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paricalcitol in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Peking University People's Hospital. Primary endpoints: Intact parathyroid hormone (iPTH), Parathyroid gland size and 1 more. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2000034476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034476.